目的 探索注射用丹参多酚酸对职业性急性化学物中毒性神经系统疾病、轻度中毒性脑病患者的疗效。方法 选取2018年6月—2019年6月于黑龙江省第二医院住院的29例职业性急性化学物中毒性神经系统疾病、轻度中毒性脑病患者作为研究对象，将患者随机分为对照组（14例）和观察组（15例）。对照组均给予常规治疗，包括纠正脑缺氧、改善脑血循环、减轻脑水肿、降低颅内压等措施，观察组在常规治疗基础上静滴注射用丹参多酚酸，将注射用丹参多酚酸0.13 g加入到0.9%氯化钠250 mL，1次/d。两组疗程为14 d。比较两组患者治疗前后颅内段血管彩超血流速度及蒙特利尔认知评估量表（MoCA）评分。结果 治疗后，两组患者血流速度均显著改善（P<0.05）；且观察组颅内动脉流速恢复明显优于对照组（P<0.05）。治疗后，两组MoCA评分均显著升高（P<0.05）；且观察组MoCA评分优于对照组（P<0.05）。结论 在常规疗法基础上联合注射用丹参多酚酸治疗职业性急性化学物中毒性神经系统疾病、轻度中毒性脑病，可有效改善颅内段血管彩超血流速度，从而改善患者头晕、头痛等不适症状，并有效提高患者认知功能。

Objective To explore the effect of Salvianolic Acid for Injection on patients with occupational acute chemical toxic neurological disease and mild toxic encephalopathy. Methods Patients (29 cases) with occupational acute chemical toxic neurological disease and mild toxic encephalopathy from June 2018 to June 2019 in the Second Hospital of Heilongjiang Province were divided into control (14 cases) and observation (15 cases) group. Patients in the control group was given routine treatment, including correction of cerebral hypoxia, improvement of cerebral blood circulation, alleviation of cerebral edema, and reduction of intracranial pressure, etc. Patients in the observation group were iv administered with Salvianolic Acid for Injection on the basis of control group, 0.13 g added into 0.9% sodium chloride 250 mL, once daily. Results After treatment, blood flow velocity in two groups was significantly improved (P < 0.05). And the intracranial arterial flow rate of the observation group was significantly better than that of the control group (P < 0.05). After treatment, MoCA scores in two groups were significantly increased (P < 0.05). And MoCA score in the observation group was better than that in the control group (P < 0.05). Conclusion Salvianolic Acids for Injection in treatment of patients with occupational acute chemotoxic nervous system disease and mild toxic encephalopathy on the basis of conventional therapy can effectively improve the blood flow velocity of intracranial vascular color doppler ultrasound, thereby improving the patient's dizziness, headache and other uncomfortable symptoms, and effectively improve the patient's cognitive function.

R969.4